Winning Genes: How to Create, Grow and Sustain a Successful Life Sciences Company

10 May 2011 Cambridge, MA Past Event

Location

Genzyme Conference Center
500 Kendall Street
Cambridge, MA

Contact Information

Meg Ryan
mryan@foley.com

Agenda

8:00 a.m. - Registration
8:45 a.m. to 3:30 p.m. - Program & Lunch
Today’s life sciences environment is experiencing a slow but steady rebound. Just as we’ve learned in research labs, building blocks from the survival gene to the social and protective genes, are the critical factors of adaptability and resilience, essential to a company’s survival. 

Dynamic market changes demand new approaches to long and short-term financial strategies, fresh perspective on licensing and collaborations and risk management strategies to sustain both early and established life sciences companies.  

Foley & Lardner along with our event partners, BioMed Realty Trust and Berkley Life Sciences present, “Winning Genes: How to Create, Grow and Sustain a Successful Life Sciences Company”. During this half-day conference, financial advisors, industry leaders and legal counsel will provide insight on critical business and legal issues during the following interactive panels:

  • Post-Recession Life Sciences: Achieving the Successful Exit in the Market Resurgence
  • The Nuts & Bolts: Designing and Implementing a Risk Management Plan
  • Match Making: Identifying Partners, Creative Collaborations and Long Term Outcomes
  • Avoiding the Pitfalls and Overcoming the Obstacles When Working with Foreign Companies

Special Keynote Presentation
We are pleased to host, Dr. Robert Langer, Institute Professor at MIT, as our keynote speaker. Dr. Langer will enlighten attendees by providing his perspective on how biotechnology entrepreneurs can succeed in today's post-recession market and share a forward looking perspective on the where the industry is heading as it relates to technology innovation and venture capitalism.

For additional information please contact Meg Ryan at mryan@foley.com.

Presentation and Materials

In today’s market,  life science  companies large and small are adjusting their collaboration and licensing strategies to account for a more robust economic outlook.  These strategies have created new options for smaller companies while larger companies are engaging in partnerships that may potentially minimize their risks.  During this interactive panel speakers will cover the following aspects of short and long term deal making:

  • How does big biopharma identify new targets?
  • Why does big biopharma pass?
  • How should early stage companies prepare for a strategic collaboration and how they can increase their leverage
  • advance product development between financing roundsand partnerships in effort to attract big biopharma collaborators
  • Strategies for advancing non-core product developmentwhile maintaining investment in priority
  • How do VCs value licensing and collaborations

Moderated by:

  • Mike Morency, Partner, Foley & Lardner LLP

Speakers:

  • David A. Charapp, Special Counsel, Foley & Lardner LLP
  • John Delyani, Head Therapeutics, Strategic Alliances, Novartis
  • Gerry Brunk, Managing Director, Lumira Capital

Coming off of a challenging economic recession, exit strategies in the life sciences industry are changing. Still adapting to the short term effects of the recession, new approaches to exits are being established which will have a long term impact on the industry. A panel of venture capitalists, investment bankers and entrepreneurs will discuss short and long term strategies for taking a life sciences company to the next level.

  • How VC’s are positioning their portfolio companies for exits
  • M&A strategies – what are large companies strategic acquisition plans in the short and long term
  • State of the IPO – is it attainable for pharma and biotech
  • What early and mid-stage companies need to do to plan for various exits

Moderated by:

  • Ron Eppen, Partner, Foley & Lardner LLP

Speaker:

  • Fouad Azzam, General Partner, LSP

The cost of research and development in the life sciences industry continues to rise along with the financial liability risks a company takes on as it commercializes products. These R&D and regulatory challenges create a perfect storm, as a result, the development of a risk management plan is more important than ever. For corporate executives and investors alike, when it comes to product development it is never too early to have your risk management plan in place.

During this interactive panel, speakers will discuss the following:

  • 10 critical risk management procedures start-up and mid-sized life sciences companies should have in place
  • In today’s product liability and regulatory landscape what risks should be addressed in clinical trials and disclosures
  • How to navigate the claims process to preserve insurance coverage and boost claim defense
  • What is the financial impact for companies when making a claim

Moderated by:

  • Emily Urban, Global Field Officer, Senior Vice President, Berkley Life Sciences

Speakers:

  • Ron Kaufman, Director of Risk Management, Genzyme
  • Kevin M. Quinley, Vice President of Risk Management Resources, Berkley Life Sciences
  • Mark J. Waxman, Partner, Foley & Lardner LLP

For companies entering biotech and pharmaceutical markets in Europe and China, regulatory and IP challenges can easily impact business endeavors and halt your expansion plans. Proper planning and knowledge on common pitfalls can make the difference between a successful foreign venture and a failure.

This session will explore the following topics:

  • Inventorship & IP issues across borders – who owns what?
  • Joint ventures and deal making: what the Chinese and EU regulate
  • Identifying and working with Contract Research Organizations (CROs)
  • Navigating the challenges with regulatory controls and approvals in the EU

Moderated by:

  • Sven Riethmueller, Partner, Foley & Lardner LLP

Speaker:

  • Jim Ewing, Partner, Foley & Lardner LLP
  • Chuck Abdalian, Senior Life Sciences Executive, Former Senior Vice President and Chief Financial Officer of Molecular Insight Pharmaceuticals, Inc.
  • Travis Wilson, CEO, Stealth Peptides Inc. and a member of the Morningside Group

Winning Genes: How to Create, Grow and Sustain a Successful Life Sciences Company

Location

Genzyme Conference Center
500 Kendall Street
Cambridge, MA

Contact Information

Meg Ryan
mryan@foley.com

Agenda

8:00 a.m. - Registration
8:45 a.m. to 3:30 p.m. - Program & Lunch